Lisa RydÃ©n

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1204267/publications.pdf

Version: 2024-02-01

102 papers	4,117 citations	145106 33 h-index	150775 59 g-index
107 all docs	107 docs citations	107 times ranked	7365 citing authors

#	Article	IF	Citations
1	Abstract PD9-05: Prognostic and tamoxifen-predictive effect of PAM50 and ROR score in premenopausal women included in the randomised SBII:2 trial. Cancer Research, 2022, 82, PD9-05-PD9-05.	0.4	0
2	The NILS Study Protocol: A Retrospective Validation Study of an Artificial Neural Network Based Preoperative Decision-Making Tool for Noninvasive Lymph Node Staging in Women with Primary Breast Cancer (ISRCTN14341750). Diagnostics, 2022, 12, 582.	1.3	7
3	Abstract P1-01-09: Prediction of node negative breast cancer and high disease burden through image analysis software on mammographic images and clinicopathological data. Cancer Research, 2022, 82, P1-01-09-P1-01-09.	0.4	0
4	Abstract P2-08-11: How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer. Cancer Research, 2022, 82, P2-08-11-P2-08-11.	0.4	0
5	The Prognostic Role of Intratumoral Stromal Content in Lobular Breast Cancer. Cancers, 2022, 14, 941.	1.7	5
6	Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial. Breast, 2022, 63, 16-23.	0.9	14
7	Feasibility and Relevance of an Intervention with Systematic Screening as a Base for Individualized Rehabilitation in Breast Cancer Patients: A Pilot Trial of the ReScreen Randomized Controlled Trial. Journal of Multidisciplinary Healthcare, 2022, Volume 15, 1057-1068.	1.1	2
8	PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients. Npj Breast Cancer, 2022, 8, 61.	2.3	5
9	Peripheral Blood Mononuclear Cell Populations Correlate with Outcome in Patients with Metastatic Breast Cancer. Cells, 2022, 11, 1639.	1.8	8
10	The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer. Breast Cancer Research and Treatment, 2022, 194, 577-586.	1.1	7
11	St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study. British Journal of Surgery, 2021, 108, 1465-1473.	0.1	1
12	Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer. BMC Cancer, 2021, 21, 185.	1.1	8
13	PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications. Cancers, 2021, 13, 1592.	1.7	11
14	Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab028.	1.4	20
15	Psychological Resilience and Health-Related Quality of Life in 418 Swedish Women with Primary Breast Cancer: Results from a Prospective Longitudinal Study. Cancers, 2021, 13, 2233.	1.7	11
16	Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer. Breast Cancer Research and Treatment, 2021, 189, 131-144.	1.1	13
17	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 2021, 154, 128-137.	1.3	24
18	Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study. Redox Biology, 2021, 47, 102145.	3.9	40

#	Article	IF	Citations
19	The PROCEM study protocol: Added value of preoperative contrast-enhanced mammography in staging of malignant breast lesions - a prospective randomized multicenter study. BMC Cancer, 2021, 21, 1115.	1.1	5
20	High Levels of Expression of Cartilage Oligomeric Matrix Protein in Lymph Node Metastases in Breast Cancer Are Associated with Reduced Survival. Cancers, 2021, 13, 5876.	1.7	6
21	Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study. Acta OncolÃ³gica, 2020, 59, 1528-1537.	0.8	11
22	Psychological Resilience and Health-Related Quality of Life in Swedish Women with Newly Diagnosed Breast Cancer . Cancer Management and Research, 2020, Volume 12, 12041-12051.	0.9	14
23	The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breastâ€"Long-Term Prognostic Significance. Cells, 2020, 9, 1718.	1.8	10
24	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nature Communications, 2020, 11, 3747.	5.8	53
25	Co-localization of CD169 ⁺ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression. OncoImmunology, 2020, 9, 1848067.	2.1	9
26	Psychometric properties of the Connor-Davidson Resilience Scale (CD-RISC) in a non-clinical population in Sweden. Health and Quality of Life Outcomes, 2020, 18, 132.	1.0	44
27	Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Scientific Reports, 2020, 10, 4484.	1.6	14
28	The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer. Breast Cancer Research and Treatment, 2020, 180, 167-176.	1.1	9
29	Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells. International Journal of Molecular Sciences, 2020, 21, 2885.	1.8	9
30	Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. PLoS ONE, 2020, 15, e0231786.	1.1	15
31	Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression. Breast Cancer Research and Treatment, 2020, 181, 369-381.	1.1	25
32	Barriers and facilitators for individualized rehabilitation during breast cancer treatment â€“ a focus group study exploring health care professionalsâ€™ experiences. BMC Health Services Research, 2020, 20, 252.	0.9	15
33	Added value of contrast-enhanced mammography (CEM) in staging of malignant breast lesionsâ€"a feasibility study. World Journal of Surgical Oncology, 2020, 18, 100.	0.8	13
34	Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Research, 2020, 22, 140.	2.2	25
35	The mutational landscape of the <scp>SCAN</scp> â€B realâ€world primary breast cancer transcriptome. EMBO Molecular Medicine, 2020, 12, e12118.	3.3	36
36	Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. Life Science Alliance, 2020, 3, e202000893.	1.3	14

#	Article	IF	Citations
37	Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq within the Sweden Cancerome Analysis Network: Breast Project (SCAN-B; NCT03430492).. Journal of Clinical Oncology, 2020, 38, 518-518.	0.8	2
38	Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. Clinical Cancer Research, 2019, 25, 6368-6381.	3.2	37
39	Artificial neural network models to predict nodal status in clinically node-negative breast cancer. BMC Cancer, 2019, 19, 610.	1.1	26
40	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	1.6	39
41	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	1.1	23
42	Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment. Breast Cancer Research and Treatment, 2019, 177, 447-455.	1.1	14
43	Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics, 2019, 20, 503.	1.2	75
44	Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases. BMC Cancer, 2019, 19, 626.	1.1	13
45	The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment, 2019, 175, 305-316.	1.1	8
46	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533.	15.2	218
47	The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence. Breast Cancer Research and Treatment, 2018, 169, 231-241.	1.1	60
48	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. British Journal of Surgery, 2018, 105, e158-e168.	0.1	32
49	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nature Medicine, 2018, 24, 463-473.	15.2	120
50	Clinical Value of RNA Sequencingâ€“Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Networkâ€”Breast Initiative. JCO Precision Oncology, 2018, 2, 1-18.	1.5	101
51	Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer. BMC Cancer, 2018, 18, 1226.	1.1	3
52	Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Research, 2018, 20, 48.	2.2	80
53	Stability of oestrogen and progesterone receptor antigenicity in formalinâ€fixed paraffinâ€embedded breast cancer tissue over time. Apmis, 2018, 126, 746-754.	0.9	4
54	Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients. World Journal of Surgical Oncology, 2018, 16, 54.	0.8	12

#	Article	IF	Citations
55	A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study. BMC Cancer, 2018, 18, 789.	1.1	11
56	Nomograms for preoperative prediction of axillary nodal status in breast cancer. British Journal of Surgery, 2017, 104, 1494-1505.	0.1	55
57	Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 606.e9-606.e16.	0.8	30
58	Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer, 2017, 17, 379.	1.1	109
59	Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta OncolÃ³gica, 2017, 56, 68-74.	0.8	51
60	Tumor tissue protein signatures reflect histological grade of breast cancer. PLoS ONE, 2017, 12, e0179775.	1.1	8
61	Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget, 2017, 8, 45544-45565.	0.8	38
62	A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation. OncoTargets and Therapy, 2016, Volume 9, 7095-7103.	1.0	17
63	ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. BMC Cancer, 2016, 16, 904.	1.1	82
64	Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer, 2016, 16, 433.	1.1	125
65	Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial. Journal of Clinical Oncology, 2016, 34, 2232-2238.	0.8	30
66	The accuracy of preoperative axillary nodal staging in primary breast cancer by ultrasound is modified by nodal metastatic load and tumor biology. Acta OncolÃ³gica, 2016, 55, 976-982.	0.8	18
67	Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo â€“ Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast, 2016, 26, 106-114.	0.9	56
68	Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. PLoS ONE, 2016, 11, e0150977.	1.1	9
69	Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. PLoS ONE, 2015, 10, e0127028.	1.1	116
70	Serial monitoring of circulating tumor <scp>DNA</scp> in patients with primary breast cancer for detection of occult metastatic disease. EMBO Molecular Medicine, 2015, 7, 1034-1047.	3.3	380
71	Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases. Clinical Proteomics, 2015, 12, 13.	1.1	15
72	A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. Journal of Translational Medicine, 2015, 13, 126.	1.8	23

#	Article	IF	Citations
73	The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine, 2015, 7, 20.	3.6	129
74	Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy. European Journal of Cancer, 2015, 51, 2304-2313.	1.3	8
75	Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. Cell Reports, 2015, 12, 1968-1977.	2.9	164
76	Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. Breast Cancer Research, 2015, 17, 102.	2.2	30
77	Transurethral Bladder Tumor Resection Can Cause Seeding of Cancer Cells into the Bloodstream. Journal of Urology, 2015, 193, 53-57.	0.2	69
78	Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. Oncotarget, 2015, 6, 37169-37184.	0.8	25
79	The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRÎ±, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e102176.	1.1	49
80	Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. SpringerPlus, 2014, 3, 70.	1.2	14
81	A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. Journal of Leukocyte Biology, 2014, 96, 685-693.	1.5	128
82	The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naÃ¯ve women with N0/N1 primary breast cancer. SpringerPlus, 2013, 2, 111.	1.2	12
83	Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10Âyearsâ€™ follow-up. Breast Cancer Research and Treatment, 2013, 140, 93-104.	1.1	47
84	St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer, 2013, 13, 558.	1.1	45
85	Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Molecular Oncology, 2012, 6, 494-506.	2.1	136
86	Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer, 2012, 12, 403.	1.1	22
87	Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes and Cancer, 2012, 51, 375-383.	1.5	31
88	Stromal Expression of Î²-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer. Journal of Molecular Diagnostics, 2011, 13, 340-351.	1.2	23
89	Analysis of sentinel node biopsy - a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols. Histopathology, 2011, 59, 129-138.	1.6	19
90	Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer, 2011, 11, 114.	1.1	33

#	Article	IF	Citations
91	Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer, 2011, 11, 341.	1.1	76
92	Evidence for tissue factor phosphorylation and its correlation with proteaseâ€activated receptor expression and the prognosis of primary breast cancer. International Journal of Cancer, 2010, 126, 2330-2340.	2.3	74
93	Challenges in Developing New Biomarkers for Breast Cancer: Reply. World Journal of Surgery, 2010, 34, 2792-2793.	0.8	0
94	Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Research and Treatment, 2010, 120, 491-498.	1.1	69
95	17ÃŸ-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. European Journal of Cancer, 2010, 46, 892-900.	1.3	8
96	Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?. World Journal of Surgery, 2010, 34, 1434-1441.	0.8	44
97	Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer â€“ A national survey performed at pathology departments in Sweden. Acta OncolÃ³gica, 2009, 48, 860-866.	0.8	22
98	Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. European Journal of Cancer, 2009, 45, 2496-2502.	1.3	34
99	HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Research and Treatment, 2008, 109, 351-357.	1.1	31
100	Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Research and Treatment, 2005, 89, 135-143.	1.1	58
101	Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer. Journal of Clinical Oncology, 2005, 23, 4695-4704.	0.8	80
102	Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. European Journal of Cancer, 2005, 41, 256-264.	1.3	92